Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Sarcoma, Ewing 1Prostatic Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Colorectal Neoplasms 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × figitumumab × Clear all
NCT00635245 2015-03-11

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Pfizer

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00976508 2013-12-13

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Pfizer

Phase 1 Terminated
24 enrolled 10 charts
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡